Bladder cancer, version 5.2017: Clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 15, Issue 10, 2017, Pages 1240-1267

  Spiess, Philippe E ^a   Agarwal, Neeraj ^b   Bangs, Rick ^ac   Boorjian, Stephen A ^a   Buyyounouski, Mark K ^c   Clark, Peter E ^d   Downs, Tracy M ^e   Efstathiou, Jason A ^f   Flaig, Thomas W ^g   Friedlander, Terence ^h   Greenberg, Richard E ⁱ   Guru, Khurshid A ^j   Hahn, Noah ^k   Herr, Harry W ^l   Hoimes, Christopher ^m   Inman, Brant A ⁿ   Jimbo, Masahito ^o   Kader, A Karim ^p   Lele, Subodh M ^q   Meeks, Joshua J ^r   Michalski, Jeff ^s   Montgomery, Jeffrey S ^o   Pagliaro, Lance C ^t   Pal, Sumanta K ^u   Patterson, Anthony ^v   Plimack, Elizabeth R ⁱ   Pohar, Kamal S ^w   Porter, Michael P ^x   Preston, Mark A ^y   Sexton, Wade J ^a   Siefker Radtke, Arlene O ^z   Sonpavde, Guru ^aa   Tward, Jonathan ^b   Wile, Geoffrey ^d   Dwyer, Mary A ^ab   Gurski, Lisa A ^ab   more..

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^g University of Colorado Cancer Center   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j ROSWELL PARK CANCER INSTITUTE   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ DUKE CANCER INSTITUTE   (United States)

^o UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^p UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^q UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^r NORTHWESTERN UNIVERSITY   (United States)

^s BARNES JEWISH HOSPITAL   (United States)

^t MAYO CLINIC CANCER CENTER   (United States)

^u CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^v UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^w OHIO STATE UNIVERSITY   (United States)

^x SEATTLE CANCER CARE ALLIANCE   (United States)

^y DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^z UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^aa UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ab NCCN   (United States)

^ac NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CYSTECTOMY; DISTANT METASTASIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; METASTASIS; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; PRACTICE GUIDELINE; REVIEW; SYSTEMIC THERAPY; BLADDER TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME; TUMOR INVASION;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85030858287     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2017.0156     Document Type: Review

References (101)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67:7-30.
2. Cancer Stat Facts: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed July 25, 2017.
3. Moch H, Humphrey PA, Ulbright TM, Reuter VE. Tumours of the Urinary Tract. In: WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed. Lyon, France: IARC; 2016.
4. Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016; 70:106-119.
5. Athanazio DA, Trpkov K. What is new in genitourinary pathology? Recent developments and highlights of the new 2016 World Health Organization classification of tumors of the urinary system and male genital organs. Applied Cancer Research 2016; 36:1.
6. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009; 3:S193-198.
7. Siefker-Radtke A. Urachal adenocarcinoma: a clinician's guide for treatment. Semin Oncol 2012; 39:619-624.
8. Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. Radiographics 2012; 32:371-387.
9. Solsona E, Iborra I, Collado A, et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 2010; 184:475-480.
10. Leibovici D, Kassouf W, Pisters LL, et al. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 2007; 70:473-476.
11. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51:137-149; discussion 149-151
12. Leissner J, Hohenfellner R, Thuroff J W, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000; 85:817-823.
13. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167:1295-1298.
14. Herr H W, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22:2781-2789.
15. Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003; 169:946-950.
16. Wright JL, Lin D W, Porter M P. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008; 112:2401-2408.
17. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866.
18. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45:297-303.
19. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and metaanalysis. J Urol 2004; 171:561-569.
20. Vashistha V, Quinn DI, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer 2014; 14:966.
21. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005; 48:202-205; discussion 205-206
22. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29:2171-2177.
23. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50-54.
24. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014; 32:1895-1901.
25. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014; 32:1889-1894.
26. McConkey DJ, Choi W, Shen Y, et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 2016; 69:855-862.
27. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005-4013.
28. Galsky MD, Stensland KD, Moshier E, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol 2016; 34:825-832.
29. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014; 66:42-54.
30. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 2009; 27:5680-5684.
31. Lehmann J, Franzaring L, Thuroff J, et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006; 97:42-47.
32. Stockle M, Wellek S, Meyenburg W, et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 1996; 48:868-875.
33. Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-464; discussion 464-457
34. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48:189-199; discussion 199-201
35. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638-2646.
36. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113:2471-2477.
37. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18:3068-3077.
38. Novotny V, Froehner M, May M, et al. Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World J Urol 2015; 33:1753-1761.
39. Ku JH, Kim M, Jeong C W, et al. Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients. Int J Radiat Oncol Biol Phys 2014; 89:1032-1037.
40. Christodouleas J P, Baumann BC, He J, et al. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer 2014; 120:1272-1280.
41. Zaghloul MS, Awwad HK, Akoush HH, et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys 1992; 23:511-517.
42. Zaghloul MS, Christodouleas J P, Smith A, et al. Adjuvant sandwich chemotherapy and radiation versus adjuvant chemotherapy alone for locally advanced bladder cancer [abstract]. Int J Radiat Oncol Biol Phys 2016; 96:Abstract S94.
43. Gakis G, Efstathiou J, Lerner S P, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013; 63:45-57.
44. Bladder cancer: diagnosis and management. National Institute for Health and Care Excellence Web site. Available at: https://www.nice.org.uk/guidance/ng2. Accessed August 7, 2017.
45. Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol 2017; 198:552-559.
46. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 2011; 185:72-78.
47. Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013; 63:823-829.
48. Herr H W, Bajorin D F, Scher HI. Neoadjuvant chemotherapy and bladdersparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16:1298-1301.
49. Splinter T, Denis L. Restaging procedures, criteria of response, and relationship between pathological response and survival. Semin Oncol 1990; 17:606-612.
50. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11:2150-2157.
51. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62-67; discussion 67-68
52. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16:3576-3583.
53. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071.
54. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012; 61:705-711.
55. Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur Urol 2017; 71:952-960.
56. Zapatero A, Martin De Vidales C, Arellano R, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology 2012; 80:1056-1062.
57. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000; 5:471-476.
58. Hagan M P, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57:665-672.
59. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009; 73:833-837.
60. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013; 14:863-872.
61. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladdersparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055-4061.
62. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2901-2907.
63. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366:1477-1488.
64. Herr HW Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987; 138:1162-1163.
65. Mak RH, Zietman AL, Heney NM, et al. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008; 102:1345-1353.
66. Picozzi S, Ricci C, Gaeta M, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13, 185 patients. J Urol 2012; 188:2046-2054.
67. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18:1921-1927.
68. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608.
69. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II - results of EORTC study 30986. J Clin Oncol 2009; 27:5634-5639.
70. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30:1107-1113.
71. Burch PA, Richardson RL, Cha SS, et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 2000; 164:1538-1542.
72. Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001; 19:3018-3024.
73. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000; 18:3247-3255.
74. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19:2527-2533.
75. Pectasides D, Glotsos J, Bountouroglou N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002; 13:243-250.
76. Lorusso V, Pollera C F, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34:1208-1212.
77. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15:1853-1857.
78. Papamichael D, Gallagher CJ, Oliver RT, et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997; 75:606-607.
79. Vaughn DJ, Broome CM, Hussain M, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-940.
80. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30:191-199.
81. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27:4454-4461.
82. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-2028.
83. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373:123-135.
84. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-2017.
85. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
86. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
87. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015; 372:2509-2520.
88. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-421.
89. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507:315-322.
90. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 2017; 18:212-220.
91. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376:1015-1026.
92. O'Donnell PH, Grivas P, Balar AV, et al. Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) [abstract]. J Clin Oncol 2017; 35(Suppl):Abstract 80.
93. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 2016; 387:1909-1920.
94. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389:67-76.
95. Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer. Available at: http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm. Accessed July 26, 2017.
96. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, singlearm, phase 2 trial. Lancet Oncol 2017; 18:312-322.
97. Sharma P, Bono P, Kim J W, et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer: results from the phase I/II CheckMate 032 study [abstract]. J Clin Oncol 2016; 34(Suppl):Abstract 80.
98. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34:3119-3125.
99. Powles T, O'Donnell PH, Massard C, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma [abstract]. J Clin Oncol 2017; 35(Suppl);Abstract 80.
100. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a Mmulticenter, phase Ib study. J Clin Oncol 2017; 35:2117-2124.
101. Patel MR, Ellerton JA, Infante JR, et al. Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial [abstract]. J Clin Oncol 2017; 35(Suppl):Abstract 80.